Retrospective analyses of additively manufactured subperiosteal jaw implants in the mandible.

Abstract

This multicentre retrospective study evaluates the success rate, adverse events, and patient satisfaction related to additively manufactured subperiosteal jaw implants (AMSJI®) in the mandible. The study analyses data from 40 AMSJI® implants placed between 2017 and beginning of 2024 in 19 patients with severe mandibular atrophy (Cawood-Howell classes IV-VII). The findings reveal a high level of patient satisfaction, and a survival rate of 92.5 % after an average follow-up of 804 days (SD ± 540 days). The most common post-operative adverse events were immediate oedema and temporary infection, which were generally managed with chlorhexidine mouth rinses, antibiotics, and paracetamol. One implant showed increased mobility (movement exceeding 1 mm in any direction) at the time of evaluation. Two other implants were removed due to persistent infection and suppuration, with a third implant scheduled for removal. Patient satisfaction in general was high at the time of the interview, with an average OHIP-14 score of 6.68 (SD ± 7.99) and a NRS score of 51.26 (SD ± 7.63). Mucosal recession (both buccal and lingual) was noted around 13 implants (32.25%); however, patients did not regard this as a functional or aesthetic concern. Within the limitations of a short-term follow-up period, AMSJI in the mandible shows promise as an effective option for rehabilitating patients with severe mandibular atrophy. Despite the positive results, longer-term follow-up is necessary to confirm the implant system's durability and performance over time.